Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against viral infections. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.

Abstract: Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.

Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.

Abstract: Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.

Abstract: Provided herein are aqueous pharmaceutical formulations comprising high concentrations of anisolated anti-A? protofibril antibody or a fragment thereof that binds to human A? protofibrils, such as BAN2401, arginine, polysorbate 80, and a pharmaceutically acceptable buffer.

Abstract: The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.

Abstract: The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and/or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and/or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

Abstract: An aqueous pharmaceutical formulation of a solubilizing agent with a pyridone compound that is useful as an inhibitor to non-NMDA receptors, particularly to the AMPA receptor is disclosed herein. In some embodiments the pyridone compound is supersaturated in aqueous solution at pH between 6 and 8. The formulations are particularly useful as intravenous injections.

Abstract: Systems and methods for coverage analysis using context information are described. The systems and methods can be used to obtain program code and test information for testing the program code, the test information associated with context information for providing context for testing the program code. Coverage information can be generated by testing the program code according to the test information. A first association can be generated between the context information and the test information. A second association can be generated between the context information and the program code. A third association can be generated between the coverage information and the test information. A subset of the coverage information can be determined based on the third association and a fourth association between the test information and the program code determined based on the first and second associations. An indication of the subset of the coverage information can be displayed.

Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against viral infections. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against the Zika (ZIKV) virus. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.

Abstract: Systems and methods for coverage analysis using context information are described. The systems and methods can be used to obtain program code and test information for testing the program code, the test information associated with context information for providing context for testing the program code. Coverage information can be generated by testing the program code according to the test information. A first association can be generated between the context information and the test information. A second association can be generated between the context information and the program code. A third association can be generated between the coverage information and the test information. A subset of the coverage information can be determined based on the third association and a fourth association between the test information and the program code determined based on the first and second associations. An indication of the subset of the coverage information can be displayed.

Abstract: Aa gene therapy method comprises modifying at least one CD4 molecule to form CD4mod, marking target cells with immunomagnetic beads, and killing the marked target cells. The method comprises applying a first vector that expresses TK-SR39 and applying a second vector that expresses HIV Tat and a CRISPR-CCR5 cassette to knockout CCR5. The TK-SR39 rapidly kills cells in a presence of Ganciclovir.

Abstract: The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.

Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against the Zika (ZIKV) virus. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: A method, system, and apparatus for treating a patient with HIV. A vector can be modified from a thymidine kinase gene. The modified vector is expressed in the presence of tat RNA. The modified vector is then package and delivered to HIV-infected cells. The replication of HIV is inhibited by eliminating infected cells in the presence of Ganciclovir. Modified cells are then selected utilizing transient tat RNA transfection and GFP expression. Vector-modified stem cells are then selected for transplantation back into the patient, thereby producing a normal immune system in the patient when the modified vector remains dormant in the absence of HIV tat.